

# Annik Prat

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6227355/publications.pdf>

Version: 2024-02-01

83  
papers

12,011  
citations

71004

43  
h-index

54771

88  
g-index

90  
all docs

90  
docs citations

90  
times ranked

12013  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Multifaceted Biology of PCSK9. <i>Endocrine Reviews</i> , 2022, 43, 558-582.	8.9	75
2	PCSK9 Contributes to the Cholesterol, Glucose, and Insulin Homeostasis in Seminiferous Tubules and Maintenance of Immunotolerance in Testis. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 889972.	1.8	2
3	The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	29
4	Substantial PCSK9 inactivation in $\beta$ -cells does not modify glucose homeostasis or insulin secretion in mice. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2021, 1866, 158968.	1.2	24
5	PCSK9 is not secreted from mature differentiated intestinal cells. <i>Journal of Lipid Research</i> , 2021, 62, 100096.	2.0	4
6	PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs. <i>Stem Cell Reports</i> , 2021, 16, 2958-2972.	2.3	7
7	Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2084-2094.	1.1	18
8	Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis. <i>Clinical Biochemistry</i> , 2020, 77, 20-25.	0.8	26
9	Proprotein convertase 7 (PCSK7) reduces apoB levels. <i>FEBS Journal</i> , 2020, 287, 3565-3578.	2.2	13
10	Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. <i>Cardiovascular Research</i> , 2019, 115, 510-518.	1.8	63
11	Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice. <i>JHEP Reports</i> , 2019, 1, 418-429.	2.6	51
12	Transcriptome Analysis Reveals Nonfoamy Rather Than Foamy Plaque Macrophages Are Proinflammatory in Atherosclerotic Murine Models. <i>Circulation Research</i> , 2018, 123, 1127-1142.	2.0	275
13	A single domain antibody against the Cys- and His-rich domain of PCSK9 and evolocumab exhibit different inhibition mechanisms in humanized PCSK9 mice. <i>Biological Chemistry</i> , 2018, 399, 1363-1374.	1.2	10
14	Low-density lipoprotein (LDL)-dependent uptake of Gram-positive lipoteichoic acid and Gram-negative lipopolysaccharide occurs through LDL receptor. <i>Scientific Reports</i> , 2018, 8, 10496.	1.6	47
15	Thrombin activation of protein C requires prior processing by a liver proprotein convertase. <i>Journal of Biological Chemistry</i> , 2017, 292, 10564-10573.	1.6	10
16	Endoplasmic Reticulum Stress and Ca <sup>2+</sup> Depletion Differentially Modulate the Sterol Regulatory Protein PCSK9 to Control Lipid Metabolism. <i>Journal of Biological Chemistry</i> , 2017, 292, 1510-1523.	1.6	31
17	The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9. <i>Pharmacological Reviews</i> , 2017, 69, 33-52.	7.1	90
18	Association Between Plasma Proprotein Convertase Subtilisin/Kexin Type 9 and the Presence of Metabolic Syndrome in a Predominantly Rural-Based Sub-Saharan African Population. <i>Metabolic Syndrome and Related Disorders</i> , 2017, 15, 423-429.	0.5	13

#	ARTICLE	IF	CITATIONS
19	Pcsk5 is required in the early cranio-cardiac mesoderm for heart development. <i>BMC Developmental Biology</i> , 2017, 17, 6.	2.1	10
20	Estrogen Signals Through Peroxisome Proliferator-Activated Receptor $\alpha$ 3 Coactivator 1 $\alpha$ to Reduce Oxidative Damage Associated With Diet-Induced Fatty Liver Disease. <i>Gastroenterology</i> , 2017, 152, 243-256.	0.6	132
21	Proprotein Convertase Subtilisin/Kexin type 9 affects insulin but not lipid metabolism in cystic fibrosis. <i>Clinical and Investigative Medicine</i> , 2017, 40, 59.	0.3	1
22	Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis. <i>Shock</i> , 2016, 46, 672-680.	1.0	110
23	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation. <i>Journal of Biological Chemistry</i> , 2016, 291, 16659-16671.	1.6	28
24	Liver-Specific Inactivation of the Proprotein Convertase FURIN Leads to Increased Hepatocellular Carcinoma Growth. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	15
25	Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other. <i>Journal of Biological Chemistry</i> , 2015, 290, 18609-18620.	1.6	47
26	PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice. <i>Journal of Lipid Research</i> , 2015, 56, 2133-2142.	2.0	45
27	Implication of the proprotein convertases in iron homeostasis: Proprotein convertase 7 sheds human transferrin receptor 1 and furin activates hepcidin. <i>Hepatology</i> , 2013, 57, 2514-2524.	3.6	57
28	Beyond LDL-C lowering: Distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency. <i>Atherosclerosis</i> , 2013, 228, 380-385.	0.4	34
29	Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9. <i>Lipids in Health and Disease</i> , 2013, 12, 112.	1.2	22
30	Furin Is the Primary in Vivo Convertase of Angiotensin-like 3 and Endothelial Lipase in Hepatocytes. <i>Journal of Biological Chemistry</i> , 2013, 288, 26410-26418.	1.6	43
31	Disruption of the expression of the proprotein convertase PC7 reduces BDNF production and affects learning and memory in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 17362-17367.	3.3	74
32	<em>In utero</em> Measurement of Heart Rate in Mouse by Noninvasive M-mode Echocardiography. <i>Journal of Visualized Experiments</i> , 2013, , e50994.	0.2	4
33	Modulation of Protease Activated Receptor 1 Influences Human Metapneumovirus Disease Severity in a Mouse Model. <i>PLoS ONE</i> , 2013, 8, e72529.	1.1	33
34	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1). <i>PLoS ONE</i> , 2013, 8, e64145.	1.1	183
35	Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia. <i>Atherosclerosis</i> , 2012, 223, 394-400.	0.4	92
36	Automated design of ligands to polypharmacological profiles. <i>Nature</i> , 2012, 492, 215-220.	13.7	698

#	ARTICLE	IF	CITATIONS
37	Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Reduces Melanoma Metastasis in Liver. <i>Neoplasia</i> , 2012, 14, 1122-IN5.	2.3	94
38	The biology and therapeutic targeting of the proprotein convertases. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 367-383.	21.5	647
39	Loss of Endothelial Furin Leads to Cardiac Malformation and Early Postnatal Death. <i>Molecular and Cellular Biology</i> , 2012, 32, 3382-3391.	1.1	43
40	Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice. <i>Circulation</i> , 2012, 125, 894-901.	1.6	193
41	Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation. <i>PLoS ONE</i> , 2012, 7, e41865.	1.1	98
42	Quantitative Proteomic Analysis of PCSK9 Gain of Function in Human Hepatic HuH7 Cells. <i>Journal of Proteome Research</i> , 2011, 10, 2011-2026.	1.8	15
43	The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomography. <i>Atherosclerosis</i> , 2011, 219, 455-462.	0.4	54
44	Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. <i>Nature Immunology</i> , 2011, 12, 45-53.	7.0	94
45	Inactivation of endothelial proprotein convertase 5/6 decreases collagen deposition in the cardiovascular system: role of fibroblast autophagy. <i>Journal of Molecular Medicine</i> , 2011, 89, 1103-1111.	1.7	25
46	PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke. <i>Journal of Lipid Research</i> , 2011, 52, 1383-1391.	2.0	77
47	Furin Is the Major Processing Enzyme of the Cardiac-specific Growth Factor Bone Morphogenetic Protein 10. <i>Journal of Biological Chemistry</i> , 2011, 286, 22785-22794.	1.6	52
48	In Vivo Evidence That Furin from Hepatocytes Inactivates PCSK9. <i>Journal of Biological Chemistry</i> , 2011, 286, 4257-4263.	1.6	132
49	A Novel Mouse Model of Alzheimer's Disease with Chronic Estrogen Deficiency Leads to Glial Cell Activation and Hypertrophy. <i>Journal of Aging Research</i> , 2011, 2011, 1-12.	0.4	21
50	Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 785-791.	1.1	220
51	Latent Transforming Growth Factor $\beta$ -Binding Proteins-2 and -3 Inhibit the Proprotein Convertase 5/6A. <i>Journal of Biological Chemistry</i> , 2011, 286, 29063-29073.	1.6	20
52	PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. <i>FEBS Letters</i> , 2010, 584, 701-706.	1.3	165
53	Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation. <i>Journal of Biological Chemistry</i> , 2009, 284, 28856-28864.	1.6	228
54	Genetic Variation at the Proprotein Convertase Subtilisin/Kexin Type 5 Gene Modulates High-Density Lipoprotein Cholesterol Levels. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 467-475.	5.1	33

#	ARTICLE	IF	CITATIONS
55	PCSK9 impedes hepatitis C virus infection <i>in vitro</i> and modulates liver CD81 expression. <i>Hepatology</i> , 2009, 50, 17-24.	3.6	129
56	The proprotein convertase PC5/6 is protective against intestinal tumorigenesis: in vivo mouse model. <i>Molecular Cancer</i> , 2009, 8, 73.	7.9	29
57	Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. <i>Hepatology</i> , 2008, 48, 646-654.	3.6	354
58	The activation and physiological functions of the proprotein convertases. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 1111-1125.	1.2	285
59	The Proprotein Convertase PCSK9 Induces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2. <i>Journal of Biological Chemistry</i> , 2008, 283, 2363-2372.	1.6	402
60	<i>In vivo</i> functions of the proprotein convertase PC5/6 during mouse development: Gdf11 is a likely substrate. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 5750-5755.	3.3	99
61	VACTERL/caudal regression/Currarino syndrome-like malformations in mice with mutation in the proprotein convertase <i>Pcsk5</i> . <i>Genes and Development</i> , 2008, 22, 1465-1477.	2.7	110
62	The Cellular Trafficking of the Secretory Proprotein Convertase PCSK9 and Its Dependence on the LDLR. <i>Traffic</i> , 2007, 8, 718-732.	1.3	213
63	The proprotein convertases are potential targets in the treatment of dyslipidemia. <i>Journal of Molecular Medicine</i> , 2007, 85, 685-696.	1.7	145
64	Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system. <i>Journal of Neurochemistry</i> , 2006, 98, 838-850.	2.1	99
65	The proprotein convertases and their implication in sterol and/or lipid metabolism. <i>Biological Chemistry</i> , 2006, 387, 871-7.	1.2	88
66	Deletion of the Gene Encoding Proprotein Convertase 5/6 Causes Early Embryonic Lethality in the Mouse. <i>Molecular and Cellular Biology</i> , 2006, 26, 354-361.	1.1	73
67	Miniglucagon (MG)-Generating Endopeptidase, which Processes Glucagon into MG, Is Composed of N-Ariginine Dibasic Convertase and Aminopeptidase B. <i>Endocrinology</i> , 2005, 146, 702-712.	1.4	38
68	Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 1454-1459.	1.1	557
69	NARC-1/PCSK9 and Its Natural Mutants. <i>Journal of Biological Chemistry</i> , 2004, 279, 48865-48875.	1.6	544
70	Nardilysin, A Basic Residues Specific Metallopeptidase That Mediates Cell Migration and Proliferation. <i>Protein and Peptide Letters</i> , 2004, 11, 501-508.	0.4	18
71	Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. <i>Nature Genetics</i> , 2003, 34, 154-156.	9.4	2,532
72	The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 928-933.	3.3	1,012

#	ARTICLE	IF	CITATIONS
73	Down-regulation of alphav/beta3 integrin via misrouting to lysosomes by overexpression of a beta3Lamp1 fusion protein. <i>Biochemical Journal</i> , 2003, 370, 703-711.	1.7	12
74	The metalloendopeptidase nardilysin (NRDc) is potently inhibited by heparin-binding epidermal growth factor-like growth factor (HB-EGF). <i>Biochemical Journal</i> , 2002, 367, 229-238.	1.7	24
75	Precursor convertases in the secretory pathway, cytosol and extracellular milieu. <i>Essays in Biochemistry</i> , 2002, 38, 79-94.	2.1	190
76	N-arginine dibasic convertase is a specific receptor for heparin-binding EGF-like growth factor that mediates cell migration. <i>EMBO Journal</i> , 2001, 20, 3342-3350.	3.5	115
77	Inhibition of Proprotein Convertases Is Associated with Loss of Growth and Tumorigenicity of HT-29 Human Colon Carcinoma Cells. <i>Journal of Biological Chemistry</i> , 2001, 276, 30686-30693.	1.6	156
78	N-arginine dibasic convertase (nardilysin) isoforms are soluble dibasic-specific metalloendopeptidases that localize in the cytoplasm and at the cell surface. <i>Biochemical Journal</i> , 2000, 349, 587.	1.7	29
79	N-arginine dibasic convertase (nardilysin) isoforms are soluble dibasic-specific metalloendopeptidases that localize in the cytoplasm and at the cell surface. <i>Biochemical Journal</i> , 2000, 349, 587-597.	1.7	34
80	The Kex2p Proregion Is Essential for the Biosynthesis of an Active Enzyme and Requires a C-terminal Basic Residue for Its Function. <i>Molecular Biology of the Cell</i> , 2000, 11, 1947-1957.	0.9	26
81	Human and rat testis express two mRNA species encoding variants of NRD convertase, a metalloendopeptidase of the insulinase family. <i>Biochemical Journal</i> , 1997, 327, 773-779.	1.7	27
82	Expression and retinoid modulation of N-arginine dibasic convertase and an aminopeptidase-B in human neuroblastoma cell lines. <i>Journal of Neuro-Oncology</i> , 1997, 31, 99-106.	1.4	15
83	[45] N-arginine dibasic convertase. <i>Methods in Enzymology</i> , 1995, 248, 703-716.	0.4	20